author-photo

Inga Bertucci

French Institute of Health and Medical Research

5

Papers

116

Citations

Citation Trend

Filter By

Papers (5) Sort By

Journal Conference Others

Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial

2017 The Lancet Gastroenterology & Hepatology
Show All
- Source
- Cite
- Save
Citations (57)
Pegylated Interferon α-2a Triggers NK-Cell Functionality and Specific T-Cell Responses in Patients with Chronic HBV Infection without HBsAg Seroconversion

2016 PLOS ONE
Show All
- Source
- Cite
- Save
Citations (14)
Remodeling of B-Cell Subsets in Blood during Pegylated IFNα-2a Therapy in Patients with Chronic Hepatitis B Infection.

2016 PLOS ONE
Show All
- Source
- Cite
- Save
Citations (7)
O112 : HBsAg clearance after addition of 48 weeks of pegifn in HBeAg negative CHB patients on nucleos(T)ide therapy with undetectable hbvdna for at least one year: final results from ANRS-HB06 pegan study: multicenter randomized controlled phase III trial

2015 Journal of Hepatology
Show All
- Source
- Cite
- Save
Citations (12)
Telaprevir for HIV/Hepatitis C Virus–Coinfected Patients Failing Treatment With Pegylated Interferon/Ribavirin (ANRS HC26 TelapreVIH): An Open-Label, Single-Arm, Phase 2 Trial

2014 Clinical Infectious Diseases
Show All
- Source
- Cite
- Save
Citations (26)